Oblato, Inc., a subsidiary company of HLB Therapeutics in Korea, has announced the first enrollment for recurrent high-grade glioma patients in a Phase 1 clinical trial in the USA with an oral formulation of its proprietary compound OKN-007.
Oblato, Inc., a subsidiary company of HLB Therapeutics in Korea, has announced the first enrollment for recurrent high-grade glioma patients in a Phase 1 clinical trial in the USA with an oral formulation of its proprietary compound OKN-007.